Overview

Study To Evaluate The Efficacy And Safety Of Balovaptan In Adults With Post-Traumatic Stress Disorder (PTSD)

Status:
Not yet recruiting
Trial end date:
2023-12-15
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy and safety of 10 mg of oral administration balovaptan once a day (QD) compared with matching placebo in adults with PTSD.
Phase:
Phase 2
Details
Lead Sponsor:
Hoffmann-La Roche